Effects of HSP70 antisense oligonucleotide on the proliferation and apoptosis of human hepatocellular carcinoma cells

Abstract

The study investigated the effects of heat shock protein 70 (HSP70) antisense oligonucleotide (ASODN) on the proliferation and apoptosis of a human hepatocellular carcinoma cell line (SMMC-7721 cells) in vitro. HSP70 oligonucleotide was transfected into SMMC-7721 cells by the mediation of Sofast™ transfection reagent. Inhibition rate of SMMC-7721 cells was determined by using MTT method. Apoptosis rate and cell cycle distribution were measured by flow cytometry. Immunocytochemistry staining was used to observe the expression of HSP70, Bcl-2 and Bax. The results showed that HSP70 ASODN at various concentrations could significantly inhibit the growth of SMMC-7721 cells, and the inhibition effect peaked 48 h after transfection with 400-nmol/L HSP70 ASODN. Cytometric analysis showed the apoptotic rate was increased in a dose- and time-dependent manner in the HSP70 ASODN-treated cells. The percentage of cells in the G₂/M and S phases was significantly decreased and that in the G₀/G₁ phase increased as the HSP70 ASODN concentration was elevated and the exposure time prolonged. Immunocytochemistry showed that treatment of SMMC-7721 cells with HSP70 ASODN resulted in decreased expressions of HSP70 and Bcl-2 proteins, and an increased expression of Bax protein. It was concluded that the HSP70 ASODN can inhibit the growth of the SMMC-7721 cells and increase cell apoptosis by down-regulating the expression of HSP70. HSP70 ASODN holds promise for the treatment of hepatocellular carcinoma.

Keywords

hepatocellular carcinoma / heat shock protein 70 / antisense oligonucleotide / apoptosis

References

[1] LlovetJ.M., BruixJ.. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol, 2008, 48(1): 20-37

[2] VerslypeC., Van CutsemE., DicatoM., et al.. The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008. Ann Oncol, 2009, 20(7): 1-6

[3] MosserD.D., MorimotoR.I.. Molecular chaperones and the stress of oncogenesis. Oncogene., 2004, 23(16): 2907-2918

[4] AghdassiA., PhillipsP., DudejaV., et al.. Heat shock protein 70 increases tumorigenicity and inhibits apoptosis in pancreatic adenocarcinoma. Cancer Res, 2007, 67(2): 616-625

[5] WangX.P., LiuG.Z., SongA.L., et al.. Expression and significance of heat shock protein 70 and glucoseregulated protein 94 in human esophageal carcinoma. World J Gastroenterol, 2005, 11(3): 429-432

[6] IsomotoH., OkaM., YanoY., et al.. Expression of heat shock protein (Hsp) 70 and Hsp 40 in gastric cancer. Cancer Lett, 2003, 198(2): 219-228

[7] GalignianaM.D., HarrellJ.M., O’HagenH.M., et al.. Hsp90 binding immunophilins link p53 to dynein during p53 transport to the nucleus. J Biol Chem, 2004, 279(21): 22483-22489

[8] AfanasyevaE.A., KomarovaE.Y., LarssonL.G., et al.. Drug-induced Myc-mediated apoptosis of cancer cells is inhibited by stress protein Hsp70. Int J Cancer, 2007, 121(12): 2615-2621

[9] LasunskaiaE.B., FridlianskaiaI.I., DarievaZ.A., et al.. Transfection of NS0 myeloma fusion partner cells with HSP70 gene results in higher hybridoma yield by improving cellular resistance to apoptosis. Biotechnol Bioeng, 2003, 81(4): 496-504

[10] LanneauD., de ThonelA., MaurelS., et al.. Apoptosis versus cell differentiation, role of heat shock proteins HSP90, HSP70 and HSP27. Prion, 2007, 1(1): 53-60

[11] ChumaM., SakamotoM., YamazakiK., et al.. Expression profiling in multistage hepatocarcinogenesis: Identification of HSP70 as a molecular marker of early hepatocellular carcinoma. Hepatology, 2003, 37(1): 198-207

[12] DengX.L., ChenW., CaiM.Y., et al.. Expression of class I MHC molecule, HSP70 and TAP in human hepatocellular carcinoma. World J Gastroenterol, 2003, 9(8): 1853-1855

[13] El-SeragH.B., MarreroJ.A., RudolphL., et al.. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology, 2008, 134(6): 1752-1763

[14] LlovetJ.M., BruixJ.. Molecular targeted therapies in hepatocellular carcinoma. Hepatology, 2008, 48(4): 1312-1327

[15] DaugaardM., RohdeM., JaattelaM.. The heat shock protein 70 family: highly homologous proteins with overlapping and distinct functions. FEBS Lett, 2007, 581(19): 3702-3710

[16] JohnsonJ.D., FleshnerM.. Releasing signals, secretory pathways, and immune function of endogenous extracellular heat shock protein 72. J Leukoc Biol, 2006, 79(3): 425-434

[17] CioccaD.R., CalderwoodS.K.. Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones, 2005, 10(2): 86-103

[18] CalderwoodS.K., KhalequeM.A., SawyerD.B., et al.. Heat shock proteins in cancer: chaperones of tumorigenesis. Trends Biochem Sci, 2006, 31(3): 164-172

[19] LimS.O., ParkS.G., YooJ.H., et al.. Expression of heat shock proteins (HSP27, HSP60, HSP70, HSP90, GRP78, GRP94) in hepatitis B virus-related hepatocellular carcinomas and dysplastic nodules. World J Gastroenterol, 2005, 11(14): 2072-2079

[20] WangX.P., WangQ.X., LiH.Y., et al.. Heat shock protein 70 chaperoned alpha-fetoprotein in human hepatocellular carcinoma cell line BEL-7402. World J Gastroenterol, 2005, 11(35): 5561-5564

[21] ZhaoZ.G., ShenW.L.. Heat shock protein 70 antisense oligonucleotide inhibits cell growth and induces apoptosis in human gastric cancer cell line SGC-7901. World J Gastroenterol, 2005, 11(1): 73-78

[22] HwangT.S., HanH.S., ChoiH.K., et al.. Differential, stage-dependent expression of Hsp70, Hsp110 and Bcl-2 in colorectal cancer. J Gastroenterol Hepatol, 2003, 18(6): 690-700

[23] SreedharA.S., CsermelyP.. Heat shock proteins in the regulation of apoptosis: new strategies in tumor therapy: a comprehensive review. Pharmacol Ther, 2004, 101(3): 227-2257

[24] BeereH.M.. “The stress of dying”: the role of heat shock proteins in the regulation of apoptosis. J Cell Sci, 2004, 117(Pt13): 2641-2651

[25] CoryS., HuangD.C., AdamsJ.M.. The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene, 2003, 22(53): 8590-8607